Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,145 CAD | +7,41% | +7,41% | +81,25% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Matheson
CEO | Chief Executive Officer | - | 14-06-21 |
Harry Nijjar
DFI | Director of Finance/CFO | 36 | 01-02-22 |
Mark Williams
PSD | President | 52 | 14-06-21 |
Jacqueline Groot
SEC | Corporate Secretary | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
S. Smallbone
BRD | Director/Board Member | - | 15-02-22 |
Joseph Matheson
CEO | Chief Executive Officer | - | 14-06-21 |
Mark Williams
PSD | President | 52 | 14-06-21 |
Director/Board Member | 55 | 14-06-21 | |
Babak Pedram
BRD | Director/Board Member | 43 | 23-11-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 39 786 231 | 27 910 633 ( 70,15 %) | 0 | 70,15 % |
Bedrijfsgegevens
Marvel Biosciences Corp.
505 8th Avenue South West Suite 420
T2P 1G2, Calgary
+
http://www.marvelbiotechnology.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+81,25% | 4,21 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers MRVL
- Onderneming Marvel Biosciences Corp.